Phase 2 N=12 Cemiplimab in AlloSCT/SOT Recipients With CSCC
Cutaneous Squamous Cell Carcinoma · Advanced Cancer
Primary: Rate of Renal Transplant Rejection (Cohort 2) or GVHD (Cohort 1). — 0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=74 Taking Care of Us: A Dyadic Intervention for Heart Failure Couples
Heart Failure
Primary: Change in Physical Quality of Life Scores in Couples in the TCU vs SUPPORT Condition. — 1.28; -0.03; 0.59; -0.63 units on a scale
N/A N=61 Healthy Weight for Teens
Obesity
Primary: Number of Participants With Successful Implemenmtation of BPE (Bundle of Program Enhancements) in Existing Multi-component PWM Programs — 20; 12 Participants
Phase 1 N=10 A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics
Pharmacokinetics
Primary: Time to Maximum Concentration of Kava in the Blood — 1.9; 1.2; 1.3; 1.2 hours
Phase 2 N=25 Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Primary: Number of Participants With Adverse Events — 5; 1 participants
N/A N=201 Development and Pilot Test of a Postnatal mHealth Intervention - Phase 2
Health Attitude · Knowledge, Attitudes, Practice · Post Partum Depression
Primary: Number of Participants Reporting Being Satisfied or Very Satisfied About Their Overall Intervention Experience — 90; 19 Participants
Phase 3 N=142 Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Desmoid Tumor · Aggressive Fibromatosis
Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001
Phase 2 N=131 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Hodgkin Disease · Peripheral T Cell Lymphoma
Primary: Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) — 93; 95; 85 Percentage of participants
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
N/A N=5 HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms
Primary Progressive Aphasia
Primary: Determine Changes in Language Performance After Stimulation Sessions
Phase 2 N=15 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Kaposi's Sarcoma · HIV Positive · AIDS
Primary: Objective Response Rate — 0; 7; 6 Participants
Phase 2 N=40 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastro-esophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.257 months
Phase 4 N=21 The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries
Pelvic Ring Fractures
Primary: Visual Analogue Scale — 6.0; 6.8; 5.5; 3.7 units on a scale
N/A N=100 Healthy Juntos Pilot Study
Obesity · Activity, Motor · Diet, Healthy
Primary: Change in Adolescents Physical Activity — 0.62; -0.13; -0.18; -0.05 minutes/day
Phase 4 N=242 Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
Acne Vulgaris
Primary: Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24 — -5.9; -2.7 atrophic acne scars — p=< 0.0001